High Hopes

Hematology patients are turning to cannabis for symptom relief, but should they? As of October 2017, 28 states and the District of Columbia had legalized medical or recreational marijuana. However, the plant is still...

Online Exclusives

Cellectis Relaunches Halted CAR-T Studies

The U.S. Food and Drug Administration lifted the clinical hold on two phase I trials of Cellectis’ UCART123, its gene-edited allogeneic chimeric antigen receptor...

Access to Care, Survival Are Enduring Hurdles for Patients With Sickle...

As part of an ongoing series on discrimination in the U.S., NPR reported that while life expectancy for almost every major illness is improving,...

News

From the Blood Journals

High Rates of Depression Resulting in Higher Health-Care Costs in Patients...

Depression is approximately five times more prevalent in patients with sickle cell disease (SCD) than in the general population, and it is significantly associated...
WIB_icon

Predicting the Risk and Severity of Cytokine Release Syndrome in Patients...

While treatment with CD19-directed chimeric antigen receptor (CAR) T cells has demonstrated impressive response rates of over 80% in select patients with B-cell malignancies,...

Multimedia

Mrinal Patnaik, MBBS: When Life Gives You Venoms …

In more from his pASHions interview, Mrinal Patnaik, MBBS, discusses the surprising connections between hematology and herpetology, and shares practical tips if you find...

Pulling Back the Curtain: Donna DiMichele, MD

In more from her Pulling Back the Curtain interview, Donna DiMichele, MD, tells us about her childhood in Montreal, Canada, and reflects on how...

Pulling Back the Curtain: Brian G. M. Durie, MD

In more from our interview with Dr. Durie, hear more about how interactions with his father’s doctor piqued Dr. Durie’s interest in medicine, and...

pASHions: B.Y.O.B. (Build Your Own Boat) With Joseph H. Antin, MD

In more from our interview with Dr. Antin, he offers two simple rules for starting a new hobby with your spouse, and discusses the...

On Location

Emicizumab Significantly Decreases Bleeding Rate, Compared With No Treatment in Patients With Hemophilia A

In the phase III HAVEN-1 study, preventive treatment with emicizumab significantly reduced bleeding rates, compared...

RNA Interference Therapy Fitusiran Improves Thrombin Generation in Patients With Hemophilia

The investigational RNA interference therapy fitusiran lowered levels of antithrombin in patients with hemophilia A...

Is Anticoagulant Therapy to Prevent Recurrent VTE Worth the Bleeding Risk in Older Patients With Cancer?

Though anticoagulants are common frontline treatment for patients with venous thromboembolism (VTE), patients with cancer...

Phase II Results Show Activity of Polatuzumab Vedotin Combination in DLBCL

The CD79b-targeting antibody drug conjugate polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone...

Evaluating HCT Outcomes in Patients With Beta-Thalassemia

Hematopoietic cell transplantation (HCT) is associated with a disease-free survival rate of 90 percent at...

Fourth Drug’s the Charm? Comparing Combination Therapies in the Myeloma XI Trial

Triplet combinations of anti-myeloma induction therapies lead to deeper, longer remissions than doublet combinations. Results...

Latest Headlines

Advertisement

ASH Directions

ASH Announces New Executive Committee Members, ASH Members Visit Congress, and more

The Results Are In … ASH Announces 2018 Executive Committee Members ASH announced the election of four new members to its Executive Committee, the governing...

ASH Selects Hematologists for 2017 Visitor Training Program, New MIPS Reporting Tool Available, and...

ASH Selects Hematologists from Developing Countries to Participate in Training Program The American Society of Hematology (ASH) selected 25 hematologists and medical professionals from developing...

Sign up for our e-Newsletter!

Remembering Harold Roberts and Tessa Holyoake, CRISPR Researchers Awarded Albany Medical Center Prize, and...

Remembering Harold R. Roberts, MD Harold R. Roberts, MD, a leader in the field of thrombosis and hemostasis and two-time American Society of Hematology (ASH)...

UC San Diego Researchers Receive Grant for CAR T-cell Therapy, New President at Seidman...

Theodoros N. Teknos Appointed President and Scientific Officer of University Hospitals Seidman Cancer Center Theodoros N. Teknos, MD, has been named the president and scientific...

New CDC Director Named, NIH Awards Grants for Cancer Cell Metastases, and more

Brenda Fitzgerald Named New Director of the Centers for Disease Control and Prevention Brenda Fitzgerald, MD, the Georgia Public Health Commissioner, has been appointed director...

High Hopes

Hematology patients are turning to cannabis for symptom relief, but should they? As of October 2017, 28 states and the District of Columbia had...

A Behind-the-Scenes Look at the ASH Annual Meeting

Every December, tens of thousands of researchers, clinicians, and health-care stakeholders gather for the American Society of Hematology’s (ASH) annual meeting. More than a...

Off to the CAR T Races: Bringing CAR T-Cell Therapies to Cancer Patients

August 30, 2017, marked a milestone for medicine: The cell-based gene therapy tisagenlecleucel became the first U.S. Food and Drug Administration (FDA)–approved treatment that...